Browse News
Filter News
Found 3,740 articles
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Autoimmune Hepatitis Diagnosis and Treatment Market Size Set to Soar USD 19.15 Billion by 2032
4/23/2024
The global autoimmune hepatitis diagnosis and treatment market size is projected to increase from USD 14.03 billion in 2023 to approximately USD 19.15 billion by 2032. This growth, at a CAGR of 3.3% from 2023 to 2032
-
Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
4/22/2024
Vect-Horus announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26.
-
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
4/22/2024
SNIPR Biome ApS (“SNIPR”) announces today that it has received $5.48 million from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (“CARB-X”) to co-fund a Phase 1b/2a clinical trial in hematological cancer patients.
-
Weight-Loss Drug Startup Metsera Launches with $290M, Looks to Tap Lucrative Obesity Market
4/18/2024
The clinical-stage biotech emerged from stealth on Thursday with several oral and injectable candidates, including a GLP-1 receptor agonist in Phase I trials, in an effort to challenge Novo Nordisk and Eli Lilly. -
Nearly all doses of Eli Lilly’s highly popular weight-loss drug Zepbound and type 2 diabetes medication Mounjaro will have limited availability through the second quarter of 2024, according to the regulator.
-
Morphoceuticals Names Jim Jenson, PhD as CEO to Advance AI-Guided Regenerative Medicine Technology
4/18/2024
Morphoceuticals Inc. announced the appointment of veteran biotech executive Jim Jenson, PhD, as CEO. Jenson joins a growing team and will lead the company as it advances its novel regenerative medicine technology platform.
-
With Wednesday’s readout showing symptom improvements in obstructive sleep apnea patients, Eli Lilly is preparing to file for a label expansion for its blockbuster weight-loss drug Zepbound.
-
As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.
-
RNAi Therapeutics Market Size to Climb USD 4.28 Billion by 2033
4/17/2024
The RNAi therapeutics market size reached a value of USD 1.11 billion by 2023 is expected to surge USD 4.28 billion by 2033, projections indicate an impressive CAGR of 14.9% over the forecast period 2023 – 2033, a study by Towards Healthcare.
-
Biologics Market Size to Hit Around USD 1. 37 Trillion By 2033
4/17/2024
According to the latest Research by Nova One Advisor, the global biologics market size was exhibited at USD 511.04 billion in 2024 and is projected to hit around USD 1,374.51 billion by 2033, growing at a CAGR of 10.4% during the forecast period 2024 to 2033.
-
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
4/17/2024
Ventus Therapeutics today announced results from its Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.
-
Biopharma Leaders Come Together at Veeva Commercial Summit to Advance Customer-Centric Engagement
4/17/2024
Veeva Systems (NYSE: VEEV) today announced that leaders from Bayer, Genentech, Novo Nordisk, Takeda, and others will be among the keynote speakers at the 2024 Veeva Commercial Summit, May 7-8 in Boston.
-
GLP-1 treatments are all the rage in this space, but they aren’t the only approach in development. The pipeline assets highlighted here offer a differentiated approach, potentially increasing efficacy or reducing side effects.
-
The European Medicines Agency on Friday said it found no evidence linking GLP-1 receptor agonists with suicidal thoughts and actions, following a review of patients taking Novo Nordisk’s semaglutide and liraglutide, and Eli Lilly’s dulaglutide and AstraZeneca’s exenatide.
-
Florida District Judge Roy Altman earlier this week ruled against Eli Lilly, finding that the drugmaker cannot use state law to block reformulated versions of its blockbuster weight-loss and diabetes medication tirzepatide.
-
U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033
4/12/2024
According to Nova One Advisor, the U.S. Biotechnology market size was estimated at USD 552.49 billion in 2023
-
The American Society of Health-System Pharmacists has released statistics showing the number of active and ongoing U.S. drug shortages has reached 323, the highest number since it began tracking the data.
-
Ginkgo Bioworks Previews Today's Annual Ferment Conference, Announces "Lab Data as a Service"
4/11/2024
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, is hosting its 5th annual Ferment conference.